Persistent prevention of CIPN using calmangafodipir (PledOx): Results from a placebo-controlled randomized phase II study (PLIANT) in patients with metastatic colorectal cancer (mCRC).
2016 ◽
Vol 34
(15_suppl)
◽
pp. 10018-10018
◽
Keyword(s):
Phase Ii
◽
2010 ◽
Vol 28
(15_suppl)
◽
pp. TPS189-TPS189
2014 ◽
Vol 32
(15_suppl)
◽
pp. TPS3649-TPS3649
◽